67 related articles for article (PubMed ID: 9045059)
21. Sparteine oxidation polymorphism: a family study.
Brøsen K; Otton SV; Gram LF
Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
[TBL] [Abstract][Full Text] [Related]
22. [Acetylation phenotype in Graves' disease].
Górnik W; Syrenicz A; Gawrońska-Szklarz B; Wójcicki J
Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):743-5. PubMed ID: 2641798
[TBL] [Abstract][Full Text] [Related]
23. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
Kaneko K; Atsumi T; Miyataka T
Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
[TBL] [Abstract][Full Text] [Related]
24. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
25. N-acetylation phenotyping with sulfamethazine in an Iranian population.
Sardaş S; Lahijany B; Cok I; Karakaya AE
Pharmacogenetics; 1993 Jun; 3(3):131-4. PubMed ID: 8334437
[TBL] [Abstract][Full Text] [Related]
26. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
[TBL] [Abstract][Full Text] [Related]
27. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
28. Acetylator polymorphism in multiple sclerosis.
Ladero JM; Arroyo R; De Andrés C; Jiménez-Jiménez FJ; Molina JA; Varela de Seijas E; Giménez-Roldán S; Benítez J
Acta Neurol Scand; 1994 Feb; 89(2):102-4. PubMed ID: 8191871
[TBL] [Abstract][Full Text] [Related]
29. The genetic polymorphism of sparteine metabolism.
Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
[TBL] [Abstract][Full Text] [Related]
30. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
31. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.
Eichelbaum M; Woolhouse NM
Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789
[TBL] [Abstract][Full Text] [Related]
32. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
Schellens JH; van der Wart JH; Brugman M; Breimer DD
J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
[TBL] [Abstract][Full Text] [Related]
33. No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama.
Arias TD; Jorge LF; Inaba T
Br J Clin Pharmacol; 1986 May; 21(5):547-8. PubMed ID: 3718812
[No Abstract] [Full Text] [Related]
34. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
[TBL] [Abstract][Full Text] [Related]
35. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
Horai Y; Fujita K; Ishizaki T
Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
[TBL] [Abstract][Full Text] [Related]
36. Acetylation phenotype in colorectal carcinoma.
Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
[TBL] [Abstract][Full Text] [Related]
37. Sparteine oxidation is practically abolished in quinidine-treated patients.
Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
[TBL] [Abstract][Full Text] [Related]
38. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
39. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway.
Arias TD; Inaba T; Cooke RG; Jorge LF
Clin Pharmacol Ther; 1988 Sep; 44(3):343-52. PubMed ID: 3416554
[TBL] [Abstract][Full Text] [Related]
40. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Nielsen MD; Brøsen K; Gram LF
Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
